Ocular Therapeutix officer proposes $76.6K share sale

The shares to be sold are listed as arising from restricted stock vesting under a registered plan on October 1, 2026.

Rhea-AI Filing Summary

Ocular Therapeutix, Inc. officer Jeffrey S. Heier reported a proposed sale of 10,869 common shares with an aggregate market value of $76,639.49 and an approximate sale date of October 2, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services on Nasdaq. The shares are listed as restricted stock vesting under a registered plan on October 1, 2026. The notice also reports that Heier sold 3,296 common shares for $35,532.20 on August 24, 2026.

Key Figures

Proposed shares for sale: 10,869 shares Aggregate market value: $76,639.49 Prior three-month shares sold: 3,296 shares +1 more

4 metrics

Proposed shares for sale 10,869 shares Common shares; approximate sale date October 2, 2026

Aggregate market value $76,639.49 Proposed common-share sale

Prior three-month shares sold 3,296 shares Common shares sold August 24, 2026

Prior sale gross proceeds $35,532.20 Common shares sold August 24, 2026

Key Terms

Rule 144, Restricted Stock Vesting Under a Registered Plan, aggregate market value

3 terms

Rule 144 regulatory

"the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting Under a Registered Plan financial

"Restricted Stock Vesting Under a Registered Plan"

aggregate market value financial

"aggregate market value of $76,639.49"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many OCUL shares does Jeffrey S. Heier plan to sell?

Jeffrey S. Heier reported a proposed sale of 10,869 OCUL common shares, with an aggregate market value of $76,639.49 and an approximate sale date of October 2, 2026. The shares are listed as restricted stock vesting under a registered plan on October 1, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 04:06 PM Accepted by SEC EDGAR 10/02/2026 - 04:05 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001653082
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	OCULAR THERAPEUTIX, INC.
SEC File Number	001-36554
Address of Issuer	14 CROSBY DRIVE, 3RD FLOOR BEDFORD MASSACHUSETTS 01730
Phone	781-357-4000
Name of Person for Whose Account the Securities are To Be Sold	JEFFREY S. HEIER
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	10869	76639.49	219615868	10/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/01/2026	Restricted Stock Vesting Under a Registered Plan	Issuer			10869	10/01/2026	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
JEFFREY S. HEIER 15 Crosby Drive Bedford MA 01730	Common	08/24/2026	3296	35532.20

144: Remarks and Signature

Remarks
Date of Notice	10/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jeffrey Heier
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)